Jonathan W Lischalk1, Aidan Burke2, Jessica Chew3, Christen Elledge3, Marie Gurka4, John Marshall5, Michael Pishvaian5, Sean Collins2, Keith Unger2. 1. Department of Radiation Medicine, Georgetown University Hospital, Lower Level Bles, 3800 Reservoir Road, NW, Washington, DC, 20007, USA. jonathan.lischalk@gunet.georgetown.edu. 2. Department of Radiation Medicine, Georgetown University Hospital, Lower Level Bles, 3800 Reservoir Road, NW, Washington, DC, 20007, USA. 3. Georgetown University School of Medicine, Medical Dental Building, 3900 Reservoir Road, NW, Washington, DC, 20057, USA. 4. Department of Radiation Oncology, James Graham Brown Cancer, University of Louisville Hospital, 529 S. Jackson Street, Louisville, KY, 40202, USA. 5. Lombardi Cancer Center Medical Oncology, Department of Medicine, Georgetown University Hospital, Pasquerilla Healthcare Center, 5th Floor, 3800 Reservoir Road, NW, Washington, DC, 20007, USA.
Abstract
BACKGROUND: The majority of patients with pancreatic cancer are diagnosed with metastatic disease at presentation. Nevertheless, local progression is responsible for up to 30% of deaths and can lead to significant morbidity. As a consequence, further exploration of effective methods of local control and palliation is essential. Stereotactic body radiation therapy (SBRT) is a widely utilized technique for the treatment of localized pancreatic cancer. Here, we report our experience with SBRT and chemotherapy for the local treatment of the metastatic patient population. METHODS: This single institution retrospective review analyzed 20 patients with pathologically diagnosed metastatic adenocarcinoma of the pancreas. All patients underwent fiducial placement under endoscopic ultrasound (EUS) guidance. SBRT was delivered in five fractions to a total dose of 25 to 30 Gy. Patients received concurrent (given within 1 week of the start of SBRT) or sequential chemotherapy. Local tumor control was evaluated using Response Evaluation Criteria in Solid Tumors. Toxicity was graded using Common Terminology Criteria for Adverse Events version 4.03. Local control and overall survival were reported using the Kaplan-Meier method. RESULTS: Patient median age was 64 years, and the median pre-treatment Eastern Cooperative Oncology Group performance status was 1. All patients received chemotherapy and half of the patients (10 of 20) received concurrent chemotherapy with folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, irinotecan, and oxaliplatin. Nearly all patients (19 of 20) received post-SBRT chemotherapy. Median time from pathological diagnosis to SBRT was 3.9 months. The twelve-month local control and overall survival were 43 and 53%, respectively. However, in patients with planning target volume (PTV) targets smaller than the population median, the 12-month local control was 78%. Median time to local progression (17.8 vs. 3.0 months, p = 0.02) and overall survival (24.9 vs. 8.8, p = 0.001) were also significantly improved in this smaller PTV cohort. Though not statistically significant, there was a trend towards improvement in local control (17.8 vs. 4.3 months, p = 0.17) and overall survival (16.7 vs. 9.7 months, p = 0.087) for those who received concurrent versus sequential chemotherapy, respectively. Lastly, there were no reported grade 3-5 late toxicities. CONCLUSIONS: As systemic therapies improve, the local management of pancreatic cancer will become increasingly important. Here, we report significantly improved local control with SBRT of smaller PTV tumors with concurrent chemotherapy. Five-fraction SBRT offers a quick and effective modality of local tumor control with minimal toxicity in the metastatic pancreatic cancer population.
BACKGROUND: The majority of patients with pancreatic cancer are diagnosed with metastatic disease at presentation. Nevertheless, local progression is responsible for up to 30% of deaths and can lead to significant morbidity. As a consequence, further exploration of effective methods of local control and palliation is essential. Stereotactic body radiation therapy (SBRT) is a widely utilized technique for the treatment of localized pancreatic cancer. Here, we report our experience with SBRT and chemotherapy for the local treatment of the metastatic patient population. METHODS: This single institution retrospective review analyzed 20 patients with pathologically diagnosed metastatic adenocarcinoma of the pancreas. All patients underwent fiducial placement under endoscopic ultrasound (EUS) guidance. SBRT was delivered in five fractions to a total dose of 25 to 30 Gy. Patients received concurrent (given within 1 week of the start of SBRT) or sequential chemotherapy. Local tumor control was evaluated using Response Evaluation Criteria in Solid Tumors. Toxicity was graded using Common Terminology Criteria for Adverse Events version 4.03. Local control and overall survival were reported using the Kaplan-Meier method. RESULTS:Patient median age was 64 years, and the median pre-treatment Eastern Cooperative Oncology Group performance status was 1. All patients received chemotherapy and half of the patients (10 of 20) received concurrent chemotherapy with folinic acid, fluorouracil, and oxaliplatin or fluorouracil, leucovorin, irinotecan, and oxaliplatin. Nearly all patients (19 of 20) received post-SBRT chemotherapy. Median time from pathological diagnosis to SBRT was 3.9 months. The twelve-month local control and overall survival were 43 and 53%, respectively. However, in patients with planning target volume (PTV) targets smaller than the population median, the 12-month local control was 78%. Median time to local progression (17.8 vs. 3.0 months, p = 0.02) and overall survival (24.9 vs. 8.8, p = 0.001) were also significantly improved in this smaller PTV cohort. Though not statistically significant, there was a trend towards improvement in local control (17.8 vs. 4.3 months, p = 0.17) and overall survival (16.7 vs. 9.7 months, p = 0.087) for those who received concurrent versus sequential chemotherapy, respectively. Lastly, there were no reported grade 3-5 late toxicities. CONCLUSIONS: As systemic therapies improve, the local management of pancreatic cancer will become increasingly important. Here, we report significantly improved local control with SBRT of smaller PTV tumors with concurrent chemotherapy. Five-fraction SBRT offers a quick and effective modality of local tumor control with minimal toxicity in the metastatic pancreatic cancer population.
Entities:
Keywords:
Chemoradiation; CyberKnife radiosurgery; Metastatic; Pancreatic neoplasms; Stereotactic body radiotherapy
Authors: Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria Journal: J Surg Res Date: 2011-09-05 Impact factor: 2.192
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: David Goldstein; Robert Hassan El-Maraghi; Pascal Hammel; Volker Heinemann; Volker Kunzmann; Javier Sastre; Werner Scheithauer; Salvatore Siena; Josep Tabernero; Luis Teixeira; Giampaolo Tortora; Jean-Luc Van Laethem; Rosemary Young; Darryl Neil Penenberg; Brian Lu; Alfredo Romano; Daniel D Von Hoff Journal: J Natl Cancer Inst Date: 2015-01-31 Impact factor: 13.506
Authors: Stefano Crippa; Ismael Domínguez; J Ruben Rodríguez; Oswaldo Razo; Sarah P Thayer; David P Ryan; Andrew L Warshaw; Carlos Fernández-del Castillo Journal: J Gastrointest Surg Date: 2008-03-04 Impact factor: 3.452
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245
Authors: Joseph M Herman; Daniel T Chang; Karyn A Goodman; Avani S Dholakia; Siva P Raman; Amy Hacker-Prietz; Christine A Iacobuzio-Donahue; Mary E Griffith; Timothy M Pawlik; Jonathan S Pai; Eileen O'Reilly; George A Fisher; Aaron T Wild; Lauren M Rosati; Lei Zheng; Christopher L Wolfgang; Daniel A Laheru; Laurie A Columbo; Elizabeth A Sugar; Albert C Koong Journal: Cancer Date: 2014-12-23 Impact factor: 6.860
Authors: Marie K Gurka; Christine Kim; Aiwu Ruth He; Aline Charabaty; Nadim Haddad; Jenna Turocy; Lynt Johnson; Patrick Jackson; Louis M Weiner; John L Marshall; Sean P Collins; Michael J Pishvaian; Keith Unger Journal: Am J Clin Oncol Date: 2017-04 Impact factor: 2.339
Authors: Jian Ye; Bradley N Mills; Tony Zhao; Booyeon J Han; Joseph D Murphy; Ankit P Patel; Carl J Johnston; Edith M Lord; Brian A Belt; David C Linehan; Scott A Gerber Journal: Cancer Immunol Res Date: 2019-11-12 Impact factor: 11.151
Authors: M Pavic; M Niyazi; L Wilke; S Corradini; M Vornhülz; U Mansmann; A Al Tawil; R Fritsch; J Hörner-Rieber; J Debus; M Guckenberger; C Belka; J Mayerle; G Beyer Journal: Radiat Oncol Date: 2022-01-25 Impact factor: 3.481
Authors: Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Martijn R Meijerink; Hester J Scheffer Journal: Cancers (Basel) Date: 2021-03-31 Impact factor: 6.639
Authors: Lauren M Rosati; Megan N Kummerlowe; Justin Poling; Amy Hacker-Prietz; Amol K Narang; Eun J Shin; Dung T Le; Elliot K Fishman; Ralph H Hruban; Stephen C Yang; Matthew J Weiss; Joseph M Herman Journal: Oncotarget Date: 2017-06-12